Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jochen Casper
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
Clinical Genitourinary Cancer
Oncology
Urology
Related publications
First-, Second-, Third-Line Therapy for mRCC: Benchmarks for Trial Design From the IMDC
British Journal of Cancer
Cancer Research
Oncology
Second-Line-Therapie Mit Axitinib Als Referenzstandard?
Best Practice Onkologie
Oncology
PTU-071 Methotrexate Therapy for Ulcerative Colitis in the District General Hospital Setting: A Useful Second-Line Option for Patients
Gut
Gastroenterology
Second-Line Option for Colorectal Cancer
Cancer Discovery
Oncology
Are Prognostic Indices for Brain Metastases of Melanoma Still Valid in the Stereotactic Era?
Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
Is Clifford’s Rule Still Valid? Affirmative Examples From Around the World
Still a Role for Second-Line Chemoimmunotherapy in Chronic Lymphocytic Leukemia?
Haematologica
Hematology
Is the Environmental Kuznets Curve Still Valid: A Perspective of Wicked Problems
Sustainability
Development
Management
Monitoring
Environmental Science
Renewable Energy
Energy Engineering
Law
Sustainability
Planning
Policy
Power Technology
the Environment
Geography
Is in Hospital Mortality Following EVAR Still a Valid Outcome Measure?
European Journal of Vascular and Endovascular Surgery
Surgery
Cardiovascular Medicine
Cardiology